Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real‐world data-Reference-Cited by-同舟云学术

Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real‐world data

Published:2020-04-20 Issue:3 Volume:38 Page:372-380
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Palandri Francesca¹^ORCID,Breccia Massimo²^ORCID,Tiribelli Mario³,Bonifacio Massimiliano⁴,Benevolo Giulia⁵,Iurlo Alessandra⁶,Elli Elena M.⁷,Binotto Gianni⁸,Tieghi Alessia⁹,Polverelli Nicola¹⁰^ORCID,Martino Bruno¹¹,Abruzzese Elisabetta¹²,Bergamaschi Micaela¹³,Heidel Florian H.¹⁴,Cavazzini Francesco¹⁵,Crugnola Monica¹⁶,Bosi Costanza¹⁷,Isidori Alessandro¹⁸,Auteri Giuseppe¹,Forte Dorian¹,Latagliata Roberto²^ORCID,Griguolo Davide³,Cattaneo Daniele⁶,Trawinska Malgorzata¹²,Bartoletti Daniela¹^ORCID,Krampera Mauro⁴,Semenzato Gianpietro⁸,Lemoli Roberto M.¹³,Cuneo Antonio¹⁵,Di Raimondo Francesco¹⁹,Vianelli Nicola¹,Cavo Michele¹,Palumbo Giuseppe A.¹⁹

Affiliation:

1. Institute of Hematology “L. and A. Seràgnoli” Sant'Orsola‐Malpighi University Hospital Bologna Italy

2. Division of Cellular Biotechnologies and Hematology University Sapienza Rome Italy

3. Division of Hematology and BMT, Department of Medical Area University of Udine Udine Italy

4. Department of Medicine, Section of Hematology University of Verona Verona Italy

5. Division of Hematology Città della Salute e della Scienza Hospital Torino Italy

6. Hematology Division Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy

7. Hematology Division San Gerardo Hospital, ASST Monza Italy

8. Unit of Hematology and Clinical Immunology University of Padova Padova Italy

9. Department of Hematology Azienda USL ‐ IRCCS di Reggio Emilia Reggio Emilia Italy

10. Unit of Blood Diseases and Stem Cells Transplantation, Department of Clinical and Experimental Sciences University of Brescia, ASST Spedali Civili of Brescia Brescia Italy

11. Division of Hematology Azienda Ospedaliera 'Bianchi Melacrino Morelli’ Reggio Calabria Italy

12. Division of Hematology Ospedale S. Eugenio Rome Italy

13. Clinic of Hematology, Department of Internal Medicine (DiMI) IRCCS AOU San Martino‐IST Genoa Italy

14. Internal Medicine II, Hematology and Oncology Friedrich‐Schiller‐University Medical Center Jena Germany

15. Division of Hematology University of Ferrara Ferrara Italy

16. Division of Hematology Azienda Ospedaliero‐Universitaria di Parma Parma Italy

17. Division of Hematology AUSL di Piacenza Piacenza Italy

18. Haematology and Haematopoietic Stem Cell Transplant Center, AORMN (Azienda Ospedaliera Ospedali Riuniti Marche Nord) Pesaro Italy

19. Department of Scienze Mediche, Chirurgiche e Tecnologie Avanzate “G.F. Ingrassia” University of Catania Catania Italy

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.2737

Reference44 articles.

1. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management

2. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

3. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis

4. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

5. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy;Cancer;2023-12-28

2. Bomedemstat as an investigative treatment for myeloproliferative neoplasms;Expert Opinion on Investigational Drugs;2023-10-03

3. Incidence of blast phase in myelofibrosis according to anemia severity;eJHaem;2023-07-17

4. SOHO State of the Art Updates and Next Questions | Accelerated Phase of MPN: What It Is and What to Do About It;Clinical Lymphoma Myeloma and Leukemia;2023-05

5. Efficacy and safety of combination therapies vs monotherapy of hypomethylating agents in accelerated or blast phase of Philadelphia negative myeloproliferative neoplasms: a systematic review and meta-analysis;Annals of Medicine;2023-01-16